Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 358-366

  Rogers, John D ^a   Zhao, Jamie ^a   Liu, Lida ^a   Amin, Raju D ^a   Gagliano, Kathleen D ^a   Porras, Arturo G ^a   Blum, Robert A ^a   Wilson, Michael F ^a   Stepanavage, Michael ^a   Vega, Jose M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CYTOCHROME P450 INHIBITOR; MEVINOLIN;

ARTICLE; CHOLESTEROL SYNTHESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FLUID INTAKE; FRUIT; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BEVERAGES; CITRUS; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; REFERENCE VALUES;

EID: 0032697419     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101208     Document Type: Article

References (22)

1. 1. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interactions of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
2. 2. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53:637-42.
3. 3. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993;36:457-9.
4. 4. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
5. 5. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
6. 6. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
7. 7. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46: 101-10.
8. 8. Schwartz MS, Stubbs RJ, Thornton TJ, Vyas KP, Houck DR. Comparison of the active HMG-CoA reductase inhibitors in human and dog plasma following oral doses of lovastatin and simvastatin [AAPS abstract 1494]. Third Annual AAPS National Meeting, Orlando, Florida, November 13-17, 1988.
9. 9. Stubbs RJ, Schwartz MS, Gerson RJ, Thornton TJ, Bayne WF. Comparison of plasma profiles of lovastatin (mevinolin), simvastatin (epistatin) and pravastatin (epstatin) in the dog. Drug Invest 1990;2(suppl 2):18-28.
10. 10. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A4 protein expression. J Clin Invest 1997;99:2545-53.
11. 11. Vyas KP, Prasad HK, Shimoga RP, Duggan DE. Biotransformation of lovastatin; II: in vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Dispos 1990;18:218-22.
12. 12. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
13. 13. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996;143:240-7.
14. 14. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol ExpTher 1989;248:498-505.
15. 15. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-35.
16. 16. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989;87:28S-38.
17. 17. Lees RS, Lees AM. Rhabdomyolysis from coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Engl J Med 1995;333:664-5.
18. 18. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. N Engl J Med 1988;318:46-7.
19. 19. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34.
20. 20. Agbim NE, Brater DC, Hall SD. Interaction of diltiazem with lovastatin and pravastatin [abstract]. Clin Pharmacol Ther 1997;61:20.
21. 21. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results; I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
22. 22. Downs JR, Clearfield M, Weis S, Whitney E; Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.